Evidence map›Paper›PMID 29174292›Full record

ArticleLancet (London, England)2018

Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.

Nathalie Conrad, Andrew Judge, Jenny Tran, Hamid Mohseni, Deborah Hedgecott, Abel Perez Crespillo, Moira Allison, Harry Hemingway, John G Cleland, John J V McMurray and 1 more

8 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 8 registered trials, which are not on this map. Cited by 706 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
706citing papers in PubMed, 8 pooled it
46.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04882449 completednot on this mapstarted 2021, after this paper: background citation

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF1

TypeobservationalSponsorBodyport Inc.Ran2021 to 2023Enrolled329ConditionsHeart FailureArmsBodyport Cardiac Scale
NCT05305170 unknown statusnot on this mapstarted 2021, after this paper: background citation

Plasmatic Levels of Epoxyeicosatrienoic and Dihydroxyeicosatrienoic Acids in Heart Failure

Typeobservational_patient_registrySponsorUniversity Hospital, MotolRan2021 to 2024Enrolled100ConditionsHeart FailureArmsLevels of EETs, DHETs and HETEs
NCT05329727 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Comparative Effectiveness Study Between ARNI and ACE Inhibitor/ARB Medication in Patient With Heart Failure With Reduced Ejection Fraction Using the Nationwide Population Based Real World Registry of Korean Heart Failure

TypeobservationalSponsorWonju Severance Christian HospitalRan2022 to 2025Enrolled1,000,000ConditionsHeart Failure, MortalityArmsAngiotensin receptor neprilysin inhibitor (ARNI), Renin-Angiotensin System Inhibitor (RAS inhibitor)
NCT05416879 recruitingnot on this mapstarted 2022, after this paper: background citation

Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure: A Quantitative and Qualitative Approach

TypeobservationalSponsorNewcastle UniversityRan2022 to 2026Enrolled40ConditionsHeart FailureArmsActigraph GT3X+BT
NCT06117722 unknown statusnot on this mapstarted 2024, after this paper: background citation

ESTIA: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. Multicenter, Non-interventional, Prospective, Observational Clinical Study.

TypeobservationalSponsorElpen Pharmaceutical Co. Inc.Ran2024 to 2025Enrolled210ConditionsChronic Heart FailureArmsEplerenone torasemide in chronic heart failure
NCT06377319 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Clinical Validation of an Artificial Intelligence Based Decision Support System for Predicting Risk, Diagnosis, and Progression of Heart Failure

TypeobservationalSponsorCoventry UniversityRan2024 to 2027Enrolled1,600ConditionsHeart FailureArmsCardiac Output Response to Stress (CORS) test
NCT07128784 completednot on this mapstarted 2025, after this paper: background citation

The Impact of Aerobic Exercise Training on Cardiopulmonary Exercise Capacity in Patients With Heart Failure

TypeobservationalSponsorAnkara City Hospital BilkentRan2025 to 2025Enrolled21ConditionsHeart Failure, Cardiopulmonary Exercise Test, Aerobic Capacity, Aerobic ExerciseArmsAerobic exercise
NCT07498868 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Detecting the Undetected: an Observational Cohort Study Evaluating the Health Economics, Clinical Utility, and Patient and Staff Experiences of Innovative Peptide Testing to Screen for Heart Failure in Lymphoedema Clinics

TypeobservationalSponsorSwansea Bay University Health BoardRan2026 to 2028Enrolled618ConditionsLymphedema, Lower Limb, Lymphedema, Heart Failure, Heart Failure (for Example, Fluid Overload)
3 · Its place in the literature

Who cites it

706 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,289 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Serum drug levels and medication adherence in heart failure: A comparative cohort analysis.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2026
    Article
  16. Heart failure burden and care among cardiology inpatients: insights from the Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  17. Article
  18. Observational
  19. Observational
  20. Prevalence and prognosis of multimorbidity in heart failure with mildly reduced ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article

646 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Nathalie ConradThe George Institute for Global Health, University of Oxford, Oxford, UK.
Andrew JudgeNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK; Bristol National Institute for Health Research Biomedical Research Centre, Musculoskeletal Research Unit, Southmead Hospital, University of Bristol, Bristol, UK; Medical Research Council Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK.
Jenny TranThe George Institute for Global Health, University of Oxford, Oxford, UK.
Hamid MohseniThe George Institute for Global Health, University of Oxford, Oxford, UK.
Deborah HedgecottThe George Institute for Global Health, University of Oxford, Oxford, UK.
Abel Perez CrespilloThe George Institute for Global Health, University of Oxford, Oxford, UK.
Moira AllisonThe George Institute for Global Health, University of Oxford, Oxford, UK.
Harry HemingwayThe Farr Institute of Health Informatics Research, University College London, London, UK; The National Institute for Health Research, Biomedical Research Centre, University College London Hospitals NHS Foundation Trust/University College London, London, UK.
John G ClelandRobertson Centre for Biostatistics and Clinical Trials, University of Glasgow, Glasgow, UK; National Heart & Lung Institute, Imperial College London, London, UK.
John J V McMurrayInstitute for Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Kazem RahimiThe George Institute for Global Health, University of Oxford, Oxford, UK; Deep Medicine, Oxford Martin School, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: kazem.rahimi@georgeinstitute.ox.ac.uk.
University of Oxford · GBGeorge Institute for Global Health · GBUniversity of Glasgow · GBFarr Institute · GBNIHR Bristol Biomedical Research Centre · GBOxford University Hospitals NHS Trust · GB

Funding

British Heart Foundation FS/16/10/32053Medical Research Council MC_PC_13041Medical Research Council MR/K006584/1
6 · The paper itself

Abstract

backgroundLarge-scale and contemporary population-based studies of heart failure incidence are needed to inform resource planning and research prioritisation but current evidence is scarce. We aimed to assess temporal trends in incidence and prevalence of heart failure in a large general population cohort from the UK, between 2002 and 2014.

methodsFor this population-based study, we used linked primary and secondary electronic health records of 4 million individuals from the Clinical Practice Research Datalink (CPRD), a cohort that is representative of the UK population in terms of age and sex. Eligible patients were aged 16 years and older, had contributed data between Jan 1, 2002, and Dec 31, 2014, had an acceptable record according to CPRD quality control, were approved for CPRD and Hospital Episodes Statistics linkage, and were registered with their general practice for at least 12 months. For patients with incident heart failure, we extracted the most recent measurement of baseline characteristics (within 2 years of diagnosis) from electronic health records, as well as information about comorbidities, socioeconomic status, ethnicity, and region. We calculated standardised rates by applying direct age and sex standardisation to the 2013 European Standard Population, and we inferred crude rates by applying year-specific, age-specific, and sex-specific incidence to UK census mid-year population estimates. We assumed no heart failure for patients aged 15 years or younger and report total incidence and prevalence for all ages (>0 years).

findingsFrom 2002 to 2014, heart failure incidence (standardised by age and sex) decreased, similarly for men and women, by 7% (from 358 to 332 per 100 000 person-years; adjusted incidence ratio 0·93, 95% CI 0·91-0·94). However, the estimated absolute number of individuals with newly diagnosed heart failure in the UK increased by 12% (from 170 727 in 2002 to 190 798 in 2014), largely due to an increase in population size and age. The estimated absolute number of prevalent heart failure cases in the UK increased even more, by 23% (from 750 127 to 920 616). Over the study period, patient age and multi-morbidity at first presentation of heart failure increased (mean age 76·5 years [SD 12·0] to 77·0 years [12·9], adjusted difference 0·79 years, 95% CI 0·37-1·20; mean number of comorbidities 3·4 [SD 1·9] vs 5·4 [2·5]; adjusted difference 2·0, 95% CI 1·9-2·1). Socioeconomically deprived individuals were more likely to develop heart failure than were affluent individuals (incidence rate ratio 1·61, 95% CI 1·58-1·64), and did so earlier in life than those from the most affluent group (adjusted difference -3·51 years, 95% CI -3·77 to -3·25). From 2002 to 2014, the socioeconomic gradient in age at first presentation with heart failure widened. Socioeconomically deprived individuals also had more comorbidities, despite their younger age.

interpretationDespite a moderate decline in standardised incidence of heart failure, the burden of heart failure in the UK is increasing, and is now similar to the four most common causes of cancer combined. The observed socioeconomic disparities in disease incidence and age at onset within the same nation point to a potentially preventable nature of heart failure that still needs to be tackled.

fundingBritish Heart Foundation and National Institute for Health Research.

Indexed as

AgedAge FactorsFemaleHeart FailureHumansMaleSocioeconomic FactorsUnited Kingdom

Identifiers

PMID29174292
PMCPMC5814791
OpenAlexW2770196824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

and 2 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.